New obesity drug AMG 133 enters human safety testing
NCT ID NCT04478708
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested a new drug called maridebart cafraglutide (AMG 133) in 110 adults with obesity. The main goal was to see if the drug is safe and tolerable when given as a single dose or multiple doses. Researchers also measured how the drug moves through the body. This study does not yet test whether the drug helps with weight loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
maridebart cafraglutide (AMG 133)
What this could lead to
If successful, this could point toward a new weight-loss treatment for obesity.
What could go wrong
This is an early Phase 1 trial focused on safety, not weight loss. It is small and may not lead to an effective treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim Clinical Trials
Anaheim, California, 92801, United States
-
Clinical Pharmacology of Miami, LLC
Miami, Florida, 33014, United States
-
Orange County Research Center
Tustin, California, 92780, United States